Gastroparesis Market | Industry Analysis, Size, Share, Trends, Growth and Forecast 2024 – 2033 | Pfizer Inc., GlaxoSmithKline plc., Abbott Laboratories Inc., AstraZeneca Plc., Medtronic Plc.

Overview and Scope
Gastroparesis is a medical condition characterized by the impairment or weakening of the stomach muscles, resulting in delayed emptying of stomach contents into the small intestine. Gastroparesis is treated by medications to stimulate stomach emptying and manage underlying conditions, and surgical interventions.

Sizing and Forecast
The gastroparesis market size has grown strongly in recent years. It will grow from $6.44 billion in 2023 to $6.8 billion in 2024 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to aging population, increasing prevalence of diabetes, improved understanding of gastrointestinal disorders, evolving treatment protocols, growing awareness about gastroparesis.

The gastroparesis market size is expected to see steady growth in the next few years. It will grow to $8.19 billion in 2028 at a compound annual growth rate (CAGR) of 4.8%. The growth in the forecast period can be attributed to development of novel therapeutic options, expansion of personalized medicine approaches, integration of digital health solutions, rise in healthcare infrastructure, increasing focus on early diagnosis. Major trends in the forecast period include advancements in gastric electrical stimulation therapy, growing research in stem cell therapy, adoption of minimally invasive surgical interventions, increased use of wearable health monitoring devices, focus on patient-centric care models.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/gastroparesis-global-market-report

Segmentation & Regional Insights
The gastroparesis market covered in this report is segmented –

1) By Treatment Modality: Medications, Dietary Modifications, Medical Devices, Other Therapies
2) By Gastroparesis Type: Idiopathic, Diabetic, Post- Surgical, Other Types
3) By Patient Demographics: Pediatric Gastroparesis, Adult Gastroparesis
4) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Other Distribution Channels
5) By End User: Hospitals And Clinics, Ambulatory Surgical Centers, Home Care Settings

North America was the largest region in the gastroparesis market in 2023. The regions covered in the gastroparesis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12189&type=smp

Major Driver Impacting Market Growth
The increasing prevalence of gastroparesis is expected to propel the growth of the gastroparesis market. Gastroparesis is a medical condition that stops or delays food movement from the stomach to the small intestine. Hypothyroidism, autoimmune diseases, injury to the vagus nerve, and viral stomach infections cause gastroparesis. Gastroparesis medicine tightens and contracts the muscles in the stomach wall and improves gastric emptying. For instance, in 2021, according to a research study published by Practice Update, a Netherlands-based online publisher of research articles, in 2021 the overall prevalence rate of gastroparesis was 267.7 per 100,000 persons in the US. The prevalence rate of definite gastroparesis was 21.5 per 100,000 persons. As a result, the increasing prevalence of gastroparesis is driving the growth of gastroparesis treatment.

Key Industry Players
Major companies operating in the gastroparesis market report are Pfizer Inc., GlaxoSmithKline plc., Abbott Laboratories Inc., AstraZeneca Plc., Medtronic Plc., Takeda Pharmaceutical Company Limited, Novo Nordisk AS, Johnson And Johnson Services Inc., Teva Pharmaceutical Industries Ltd, AbbVie Inc., Boston Scientific Corporation, Bausch Health Companies Inc., Cadila Pharmaceuticals Ltd., Daewoong Pharmaceutical co. ltd, ReGenXBio Inc., ANI Pharmaceuticals Inc., Dompe Farmaceutici S.p.A, Sucampo Pharmaceuticals Inc., Ironwood Pharmaceuticals Inc., Orexo AB, Theravance Biopharma Inc., RQI Partners LLC., RedHill Biopharma Ltd., Synthorx Inc., Valeant Pharmaceuticals International Inc., CinRx Pharma LLC., Ritter Pharmaceuticals Inc., Evoke Pharma Inc., Metacrine Inc., Neurogastrx Inc.

The gastroparesis market report table of contents includes:

 1. Executive Summary

2. Gastroparesis Market Characteristics

3. Gastroparesis Market Trends And Strategies

4. Gastroparesis Market – Macro Economic Scenario

5. Global Gastroparesis Market Size and Growth

…..

32. Global Gastroparesis Market Competitive Benchmarking

33. Global Gastroparesis Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Gastroparesis Market

35. Gastroparesis Market Future Outlook and Potential Analysis

36. Appendix

Explore the trending research reports from TBRC:

https://www.thebusinessresearchcompany.com/report/serviced-office-global-market-report

https://www.thebusinessresearchcompany.com/report/repair-and-maintenance-global-market-report

https://www.thebusinessresearchcompany.com/report/foundation-structure-and-building-exterior-contractors-global-market-report

Contact Us:

The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model